April 29, 2017 2:34 PM ET

Biotechnology

Company Overview of Intercept Pharmaceuticals, Inc.

Company Overview

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis in the United States and Europe. In...

450 West 15th Street

Suite 505

Floor 5

New York, NY 10011

United States

Founded in 2002

456 Employees

Phone:

646-747-1000

Fax:

646-747-1001

Key Executives for Intercept Pharmaceuticals, Inc.

Founder, Chief Executive Officer, President and Director
Age: 48
Total Annual Compensation: $1.0M
President of International
Age: 48
Total Annual Compensation: $554.4K
Chief Medical Officer and Executive Vice President of Development
Age: 62
Total Annual Compensation: $644.0K
Chief Business and Strategy Officer
Age: 43
Total Annual Compensation: $546.0K
Compensation as of Fiscal Year 2015.

Intercept Pharmaceuticals, Inc. Key Developments

Intercept Pharmaceuticals, Inc. Presents at 16th Annual Needham Healthcare Conference, Apr-04-2017 11:20 AM

Intercept Pharmaceuticals, Inc. Presents at 16th Annual Needham Healthcare Conference, Apr-04-2017 11:20 AM. Venue: Westin Grand Central Hotel, New York, New York, United States.

Intercept Pharmaceuticals, Inc. Presents at Oppenheimer 27th Annual Healthcare Conference, Mar-21-2017 03:55 PM

Intercept Pharmaceuticals, Inc. Presents at Oppenheimer 27th Annual Healthcare Conference, Mar-21-2017 03:55 PM. Venue: The Westin New York Grand Central, 212 East 42nd Street, New York, New York, United States.

Intercept Pharmaceuticals, Inc. Announces National Institute for Health and Care Excellence Approves Ocaliva (Obeticholic Acid) for Routine Use by the National Health Service in England, Wales and Northern Ireland

Intercept Pharmaceuticals, Inc. announced that the National Institute for Health and Care Excellence (NICE) has approved Ocaliva (obeticholic acid) for routine use by the National Health Service (NHS) in England, Wales and Northern Ireland. Ocaliva has been conditionally approved in the European Union for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. The NHS is expected to make Ocaliva available to patients with PBC within 90 days of NICE's final appraisal publication and Intercept will work with local reimbursement authorities to help ensure eligible patients obtain access. The most commonly reported adverse reactions were pruritus (63%) and fatigue (22%). Adverse reactions leading to discontinuation were 1% in the Ocaliva titration arm and 11% in the Ocaliva 10 mg arm. The most common adverse reaction leading to discontinuation was pruritus. The majority of pruritus occurred within the first month of treatment and tended to resolve over time with continued dosing.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Intercept Pharmaceuticals, Inc., please visit www.interceptpharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.